Results 31 to 40 of about 253,625 (250)

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer. [PDF]

Front Oncol
Introduction Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who ...
Anido-Herranz U, Fernandez-Calvo O, Ruiz-Bañobre J, Martinez-Breijo S, Fernandez-Nuñez N, Nogareda-Seoane Z, Garrido-Pumar M, Casas-Nebra J, Muñiz-Garcia G, Portela-Pereira P, Gomez-Caamaño A, Perez-Fentes DA, Santome-Couto L, Lázaro M, Molina-Diaz A, Medina-Colmenero A, Vazquez-Estevez S.   +16 more
europepmc   +2 more sources

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. [PDF]

Br J Cancer
Alkaline phosphatase (ALP) declines and pain responses can occur during radium-223 (223Ra) treatment, but their association with treatment outcomes is unclear.
O'Sullivan JM, Heinrich D, Castro E, George S, Dizdarevic S, Baldari S, Essler M, Jong IJ, Lastoria S, Hammerer PG, Tombal B, James ND, Meltzer J, Sandström P, Sartor O.   +14 more
europepmc   +2 more sources

Radium 223 chloride

Reactions Weekly
Pinto, Álvaro, Cruz, Patricia
semanticscholar   +10 more sources

Radium-223 in metastatic castration resistant prostate cancer

Asian Journal of Andrology, 2014
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals.
Winston Vuong, Oliver Sartor, Sumanta K Pal   +2 more
doaj   +2 more sources

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. [PDF]

Cancer Immunol Res
This first-in-human, randomized trial demonstrates that combining radium-223 with pembrolizumab does not significantly impact the tumor microenvironment in patients with metastatic castration-resistant prostate cancer. Data highlight that upregulation of
Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L.   +25 more
europepmc   +2 more sources

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

PLoS ONE, 2019
BackgroundRadium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP).
Andrew J Armstrong, Santosh Gupta, Patrick Healy, Gabor Kemeny, Beth Leith, Michael R Zalutsky, Charles Spritzer, Catrin Davies, Colin Rothwell, Kathryn Ware, Jason A Somarelli, Kris Wood, Thomas Ribar, Paraskevi Giannakakou, Jiaren Zhang, Drew Gerber, Monika Anand, Wen-Chi Foo, Susan Halabi, Simon G Gregory, Daniel J George   +20 more
doaj   +2 more sources

Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer [PDF]

EJNMMI Research
Background Radium-223 (Ra-223) has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with predominant osseous metastases.
Eman E. Ahmed, Jack R. Andrews, Mohamed E. Ahmed, Rimki Haloi, Lauren A. Rhodes, Mindie Mahon, Day A. Carter, Nancy Wei, Mattew P. Thorpe, Geoffrey B. Johnson, Eugene D. Kwon, Ayse Tuba Kendi   +11 more
doaj   +2 more sources

Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. [PDF]

JCO Precis Oncol
PURPOSE Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index (aBSI) and circulating
Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, Kusaka E, Otani YS, Badusi PO, Smith MR, Meneely E, Olivier K, Lowe AC, Toner M, Maheswaran S, Haber DA, Yeap BY, Lee RJ, Miyamoto DT.   +18 more
europepmc   +2 more sources

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. [PDF]

Cancers (Basel)
Simple Summary Radium-223 is used for the management of metastatic castration-resistant prostate cancer. However, the response to this treatment is poor.
Dunne VL, Wright TC, Liberal FDCG, O'Sullivan JM, Prise KM.   +4 more
europepmc   +2 more sources

Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. [PDF]

Cancers (Basel)
Simple Summary Radium 223 (Ra-223) is a radiopharmaceutical that targets tumor-induced osteoblasts (bone-forming cells). Ra-223 reduces bone pain and prolongs overall survival in men with bone-metastatic, castrate-resistant prostate cancer.
Lin SC, Yu G, Corn PG, Damasco J, Lee YC, Song JH, Navone NM, Logothetis CJ, Melancon MP, Panaretakis T, Lin SH.   +10 more
europepmc   +2 more sources